EuropeanRegulatory Gate
Investors

Deal Gate

Identify hidden market-entry cost before it becomes a portfolio problem.

Test whether the startup's product definition, regulatory route, evidence, budget and promised EU launch date describe the same commercial reality.

The central test

Can the company reach a legally supportable EU launch with the product, evidence, people, capital and time assumed in the investment case?

Start with the thesis

What does regulatory due diligence test in an investment case?

Regulatory due diligence tests whether the exact product, proposed EU route, evidence, budget and launch timeline support the investment case. “Is the product compliant?” is usually too broad. A useful review asks what must be true for the current financing plan and launch narrative to hold. It then identifies the assumptions that can change cost, time, market access or the value of existing evidence.

RouteIs the proposed classification plausible?
RunwayDoes the round reach the next value milestone?
ControlCan management close the material gaps?

Evidence review

Six connected packages—not a certificate checklist.

A strong-looking document can still cover the wrong component, claim, version or legal requirement. The review connects evidence to the exact product and investment assumptions.

Product definition

The exact configuration, intended purpose, user, environment, claims and version being underwritten.

Likely route

Applicable frameworks, classification logic, economic-operator roles and any binary questions that could change the route.

Evidence position

What existing reports and supplier documents actually cover, what is missing and who controls access.

Capital exposure

Low–high market-entry ranges, unpriced items, rework scenarios, recurring obligations and runway impact.

Critical path

Dependencies between product freeze, documentation, testing, corrective work, registration and launch.

Decision controls

Conditions precedent, named owners and 90-day milestones that make unresolved risk governable.

Investment committee output

See the conclusion, confidence and next evidence in one place.

The investor memo is written for action. It highlights material findings, downside drivers, financing consequences and the evidence that would raise or lower confidence. It does not bury the decision in a technical narrative.

Executive decision note

The key question, assessment, confidence and the reasons the conclusion could change.

Regulatory Entry Budget

Low–high ranges with sources, exclusions, recurring obligations and explicitly unpriced uncertainty.

Critical-path timeline

Dependencies and decision gates, rather than a single unsupported launch date.

Risk governance

Convert open risk into transaction conditions and 90-day milestones.

Not every unknown must be resolved before a deal closes. Material unknowns should, however, have an owner, evidence request, decision date and a consequence if the assumption fails.

  1. Before close: resolve questions that could fundamentally change the investment thesis or permitted use.
  2. At close: reserve budget and accountability for route-critical evidence and specialist work.
  3. Post close: attach measurable evidence milestones to the board plan and financing runway.

Open the fictional sample investment memo to see how those conditions can be expressed.

Important boundary

Decision support is not an investment recommendation or legal opinion.

The assessment is indicative and depends on the supplied product facts and evidence. It does not make a formal regulatory classification, certify a product, replace legal advice, or tell an investor to invest or not invest. Specialist validation may be required for higher-risk or borderline products.

Investor pilot

Pilot the method on one live deal.

Request a scoped proposal. No investor pricing is presented until the product, evidence boundary and decision question are understood.

Regulatory due diligence for physical-product deals · Regulatory Gate